Table 1 Experimental parameters and mean values of Cbl forms in different organs.

From: Linagliptin treatment is associated with altered cobalamin (VitB12) homeostasis in mice and humans

Experiment

#

All animals

(n)

Linagliptin

(n)

Treatment duration

(Days)

Organ

Cobalamin

(µg/kg chow)

Cobalamin

Type

Mean Control ± SD

[a.U.]

Mean Linagliptin ± SD

[a.U.]

p

TT

p

KW

1

38

14

84

Kidney

30

OH

0.96 ± 0.51

1.74 ± 0.80

0.0039

0.0020

CN

0.12 ± 0.06

2.37 ± 0.78

 < 0.0001

 < 0.0001

10

5

84

Liver

30

OH

0.62 ± 0.19

0.60 ± 0.41

0.9230

0.2620

CN

0.06 ± 0.01

0.15 ± 0.04

0.0011

0.0040

38

14

84

Heart

30

OH

0.24 ± 0.15

0.22 ± 0.11

0.9230

0.9760

CN

0.02 ± 0.00

0.04 ± 0.02

0.0019

0.0003

2

10

5

28

Kidney

Lina: 150

Controls: 50

OH

0.66 ± 0.36

1.10 ± 0.31

0.0459

0.1090

CN

0.61 ± 0.26

1.17 ± 0.21

0.0021

0.0040

3

10

5

4

Kidney

150

OH

1.70 ± 0.66

1.46 ± 0.52

0.4980

0.2620

CN

1.59 ± 0.16

1.76 ± 0.44

0.4200

0.5220

10

5

4

Heart

150

OH

0.10 ± 0.03

0.12 ± 0.06

0.4930

0.7490

CN

0.05 ± 0.03

0.03 ± 0.02

0.2690

0.1090

10

5

4

Liver

150

OH

0.26 ± 0.09

0.28 ± 0.14

0.8030

0.8730

CN

0.12 ± 0.04

0.09 ± 0.04

0.1230

0.0782

4

8

4

14

Kidney

30

OH

1.81 ± 0.30

1.57 ± 0.26

0.0204

0.0546

CN

1.80 ± 0.80

1.43 ± 0.17

0.0864

0.5460

8

4

14

Spleen

30

OH

0.10 ± 0.02

0.11 ± 0.02

0.1280

0.1870

CN

0.05 ± 0.01

0.06 ± 0.01

 < 0.0001

0.0001

8

4

14

Heart

30

OH

0.06 ± 0.02

0.08 ± 0.01

0.0262

0.0288

CN

0.02 ± 0.01

0.03 ± 0.01

0.5000

0.6780

  1. a.U. arbitary unit; CN cyano; KW Kruskal–Wallis; Lina linagliptin; OH hydroxy; SD standard deviation; TT Welch t-test.
  2. An overview of experiments (Exp#1–4) conducted in mice to determine the relative Cbl amount in different organs at different Vit-B12 diets and treatment durations under linagliptin and placebo. Significant p values (< 0.05) are in bold.
Back to article page